Clinical Trial Update: Cemiplimab in AlloSCT/SOT Recipients With CSCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of cemiplimab (Libtayo) in recipients of allogeneic stem cell transplant or solid organ transplant with cutaneous squamous cell carcinoma has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Cutaneous Squamous Cell Carcinoma, Advanced Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-06-12